LM Funding America, Inc. Enters into Agreement to Make Pivotal Acquisition
TAMPA, Fla., Nov. 14, 2024 (GLOBE NEWSWIRE) — LM Funding America, Inc. (NASDAQ: LMFA) (“LM Funding” or the “Company”), a […]
Actelis Networks Reports Q3 2024 Results: 200% Quarterly Revenue Growth; 46% Year-to-Date Growth Reaching $6.7 Million
FREMONT, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) — Actelis Networks, Inc. (NASDAQ: ASNS) (“Actelis” or the “Company”), a market leader […]
Crown Reports Third Quarter 2024 Results
Achieved Record Quarterly Revenue of $8.0 Million Reiterates Fourth Quarter and Full Year 2024 Revenue Guidance of $9 Million and […]
EzFill Announces 2024 Third Quarter Financial Results
— Revenue Increased 13% Year Over Year to $7.0 Million From $6.2 Million — — Gross Profit Increased 74% From […]
JBi Digital chooses Rackspace Sovereign Government Cloud for its pursuit of new customers in the UK government services sector
LONDON, Nov. 14, 2024 (GLOBE NEWSWIRE) — Rackspace Technology® (NASDAQ: RXT), a leading hybrid, multicloud, and AI technology services company, […]
ZOOZ Power Enters Standby Equity Purchase Agreement to Further Growth Strategy
Tel Aviv, Israel, Nov. 14, 2024 (GLOBE NEWSWIRE) — ZOOZ Power Ltd. (NASDAQ and TASE: ZOOZ) (“ZOOZ”), the leading provider […]
PharmAla Reaches Agreement in Principle to Supply MDMA to Clinical Trial in Exchange for Full Data License
TORONTO, Nov. 14, 2024 (GLOBE NEWSWIRE) — PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:MDXXF), a biotechnology […]
Jamf Achieves Microsoft Azure’s IP Co-Sell Top-Tier Partner Status, Announces Select Solutions Now Available in Azure Marketplace
MINNEAPOLIS , Nov. 14, 2024 (GLOBE NEWSWIRE) — Jamf (NASDAQ: JAMF), the standard in managing and securing Apple at work, […]
MIMEDX’s Advocacy to Rein in Runaway Medicare Spend for Skin Substitutes Has Yielded Significant Results with Planned Implementation of LCDs
Over 200 Unproven Skin Substitutes Will No Longer Be Covered Under Revised LCDs Company to Benefit from MACs’ Commitment to […]
ProMIS Neurosciences Announces Third Quarter 2024 Financial Results and Recent Highlights
Presented full dataset from first-in-human Phase 1a clinical trial demonstrating PMN310 was generally well-tolerated with monthly dosing and that PMN310 […]
